Related Experiment Video
Updated: Aug 6, 2026
08:49
A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
Therapeutic targets in melanoma: map kinase pathway
Frank G Haluska1, Nageatte Ibrahim
1Cancer Center and Division of Hematology/Oncology, Tufts New England Medical Center, Boston, MA 02111, USA. Fhaluska@tufts-nemc.org
Current Oncology Reports
|August 12, 2006
Summary
Melanoma pathogenesis involves genetic alterations, particularly in the RAS-BRAF-MAPK pathway. Targeting the highly mutated BRAF oncogene offers promising therapeutic strategies for melanoma treatment.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Melanoma pathogenesis is increasingly understood through genetic alterations.
- The RAS-BRAF-MAPK signaling pathway is crucial in melanoma, downstream of NRAS.
- The BRAF oncogene exhibits a high mutation rate (~60%) in melanoma.
Purpose of the Study:
- To highlight the therapeutic opportunities arising from understanding melanoma's genetic alterations.
- To emphasize the significance of the BRAF oncogene in melanoma development and treatment strategies.
Main Methods:
- Review of recent advancements in understanding melanoma genetics.
- Focus on signaling pathways, particularly RAS-BRAF-MAPK.
- Analysis of BRAF mutation rates and its implications for drug development.
Main Results:
- Genetic alterations in melanoma offer new therapeutic avenues.
- BRAF mutations are prevalent and indicate BRAF's critical role.
- BRAF is a key drug target, with specific agents under investigation.
Conclusions:
- Targeting BRAF and related pathways presents a promising therapeutic strategy for melanoma.
- Continued research into BRAF-targeted therapies and novel molecules is essential.
Related Concept Videos
01:07MAPK Signaling Cascades
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...